Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jaime Kratz

Allergy & Immunology Port Richey, FL Medical Doctor

NPI 1851391411 CMS profile 356165

8202 Washington St, Port Richey, Port Richey, FL 34668

Open in the dashboard

General payments

$134,889

949 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$93,312 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Jaime Kratz of Port Richey, FL is reported in the CMS Open Payments database as having received $134,889 across 949 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $93,312 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14,927 192
2024 General $43,153 190
2023 General $35,379 160
2022 General $23,107 143
2021 General $8,031 115
2020 General $9,256 87
2019 General $1,036 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jaime Kratz
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Jaime Kratz were reported at $14,927. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Jaime Kratz Allergy & Immunology median Middle half National median
2019 $1,036 $594 $163–$1,512 $163
2020 $9,256 $426 $106–$1,233 $114
2021 $8,031 $638 $157–$1,708 $132
2022 $23,107 $790 $205–$1,961 $149
2023 $35,379 $852 $220–$2,147 $160
2024 $43,153 $865 $203–$2,267 $164
2025 $14,927 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $56,744 206 payments
  2. GlaxoSmithKline, LLC. $32,867 162 payments
  3. Genzyme Corporation $23,571 90 payments
  4. Amgen Inc. $12,499 70 payments
  5. Regeneron Healthcare Solutions, Inc. $2,450 116 payments
  6. CSL Behring $772 44 payments
  7. Novartis Pharmaceuticals Corporation $731 34 payments
  8. Octapharma USA, Inc. $722 14 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $704 26 payments
  10. Genentech USA, Inc. $696 30 payments
  11. Other $3,134 157 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $109,366 60 payments
  2. Food and Beverage $19,261 857 payments
  3. Travel and Lodging $3,687 20 payments
  4. Consulting Fee $2,228 5 payments
  5. Education $349 7 payments
Products named General payments · program years 2019–2025
  1. TEZSPIRE Respiratory $38,155 62 payments
  2. DUPIXENT Immunology $24,098 128 payments
  3. NUCALA Immunology $23,686 68 payments
  4. FASENRA $16,475 87 payments
  5. TEZSPIRE Inflammation $12,467 67 payments
  6. NUCALA Respiratory $8,070 26 payments
  7. DUPIXENT Inflammation And Immunology $2,028 94 payments
  8. TRELEGY ELLIPTA $1,060 64 payments
  9. Hizentra $713 41 payments
  10. AIRSUPRA $611 14 payments
  11. Other $8,152 372 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

2,530

Median for Allergy/ Immunology: 449

Drug cost

$1,435,718

Median for Allergy/ Immunology: $169,700

Branded share of claims

34.6%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 124 $484,477
Dupixent Pen Dupilumab Brand 43 $177,653
Tezspire Tezepelumab-Ekko Brand 38 $159,120
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 166 $142,609
Xolair Omalizumab Brand 49 $133,656
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 12 $64,879
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 12 $53,953
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 13 $44,972
Breo Ellipta Fluticasone/Vilanterol Brand 57 $33,485
Spiriva Respimat Tiotropium Bromide Brand 34 $30,335

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$2,219,247

Of which drugs: $1,996,612

Medicare patients

456

Average age 73

Services billed

116,047

312 women, 144 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Ischemic heart disease 39%
COPD 36%
Chronic kidney disease 33%
Diabetes 28%
Depression 27%
Osteoporosis 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, tezepelumab-ekko, 1 mg J2356 Office 45 79,590 $1,125,625
Injection, omalizumab, 5 mg J2357 Office 32 16,245 $482,241
Injection, benralizumab, 1 mg J0517 Office 13 2,070 $271,763

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEZSPIRE
$18,597 38 79,590
DUPIXENT
$11,692 167 —
FASENRA
$6,952 — 2,070
NUCALA
$3,124 — —
XOLAIR
$303 49 16,245

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

949 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record